Immune Pharmaceuticals Announces Enrollment Of The First Patient Into The Phase 2 Clinical Trial With Bertilimumab In Ulcerative Colitis

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news